Product Description
Biomarkers - Database Curated from US Oncology Trials, 2021.
This new report is an interactive database of biomarkers being explored in interventional, active oncology clinical trials in the US; the platform helps track biomarkers used in trials across therapy classes, cancer indications and sponsors.
To date, biomarker data from >2,500 active and ongoing oncology clinical trials in the US has been captured and curated.
Data extracted from each trial includes:
- Biomarker
- Biomarker function
- Therapy class
- Trial phase, cancer indication, start / completion dates, enrollment, sponsors, therapies, etc.
The biomarker data is imported into Tableau™ which allows for dynamic visualization, granular interrogation, and segmentation of biomarkers by function, therapy class, cancer indication, phase, sponsor, etc.
The dashboards enable pharma, diagnostics, and research tools companies to identify emerging biomarkers of interest, assess competitive landscape, and prioritize biomarker development.
Data collected from each trial includes:
- Trial start date and phase
- Target enrollment volume
- Primary and collaborating sponsors
- Biomarker and its function
- Indication(s)
- Therapy class
- Primary tested drugs and others
- Primary and secondary endpoints
- Inclusion and exclusion criteria
- Site location
Note: Includes information only from active, interventional oncology trials in the US that are tagged with biomarker information; the database does not currently include data from trials that were completed, withdrawn, or terminated before 12/2021.
The report will enable the user to:
- Identify top and emerging oncology biomarkers as well as trends (e.g., most-cited markers, common late-stage markers), segmented by biomarker function, indication and therapy class
- Identify markers used for various functions (e.g., patient selection, efficacy)
- Identify which biomarkers have the most “patient-power” behind them (i.e., the number of patients enrolled in trials exploring each marker)
- Segment biomarker data at a very granular level (e.g., phase 2-3 lung cancer markers for patient selection)
- Evaluate emerging biomarkers for any given indication (e.g., biomarkers by indication x function)
- Identify the key and emerging players across oncology and/or for a particular biomarker
- Identify and benchmark against the biomarker and therapy activity for a particular company / competitor of interest
- Assess which companies /organizations are exploring which biomarkers
- Identify potential biomarker partners
- Explore the indications / applications being pursued by academic / research organizations that may have commercial implications
- Assess the clinical activity (e.g., number of trials, phase) and trends for oncology therapies
- Compare the biomarker strategies /focuses across different drugs and companies
- Identify oncology therapeutic strategies being pursued by various companies / organizations
- Evaluate different combination treatments
